Compumedics delivers record FY26 revenue, 72% EBITDA growth and strong cash generation

Record revenue of $60.3 million, Somfit and Nexus 360 SaaS revenue up 70%, EBITDA of $5.4 million and operating cash inflow of $6.6 million

BUSINESS UPDATE

Compumedics Limited (ASX: CMP), a global medical device company that develops, manufactures and commercialises diagnostic technology for sleep, brain and ultrasonic blood flow monitoring, provides the following FY26 results and business update in conjunction with the release of its Appendix 4E preliminary final report for the year ended 30 June 2026.

BUSINESS HIGHLIGHTS

- **Record FY26 revenue of $60.3 million**, up 18.5% on FY25
- **EBITDA of $5.4 million, up 72.1% on FY25**, with EBITDA margin increasing to approximately 9% and NPAT returning to profit at $0.2 million
- **Operating cash inflow of $6.6 million;** cash less invoice facility and overdraft improved to $5.6 million from $(1.0) million in FY25
- **Somfit and Nexus 360 SaaS revenue increased 70% to $10.2 million**, highlighting continued growth in recurring, software-enabled revenue
- **MEG contributed $9.7 million of FY26 revenue**, with approximately $13.1 million of MEG open orders entering FY27
- **FY26 sales orders of $62.7 million**, with Group open orders of approximately $28.3 million at 21 August 2026
- **Previously announced $2 million cost savings program delivered in FY26**, reflecting tighter cost discipline, organisational efficiencies and the reset of the U.S. commercial structure
- **Compumedics remains focused on further double-digit revenue growth in FY27**, with EBITDA growth at a faster rate than revenue

FY26 FINANCIAL SUMMARY

A$ million	FY26	FY25	Change
Revenue	**60.3**	50.8	+18.5%
EBITDA	**5.4**	3.1	+72.1%
EBITDA margin	**9%**	6%	+3 pts
NPAT	**0.2**	(1.3)	+$1.5m
Net operating cash flow	**6.6**	0.4	+$6.2m
Cash less invoice facility and overdraft	**5.6**	(1.0)	+$6.7m

Summary of results reported in the Company's Appendix 4E preliminary final report for the year ended 30 June 2026.

PERFORMANCE OVERVIEW: FY26

FY26 marked a material step-up in Compumedics' financial performance, with record revenue of $60.3 million, up 18.5% on FY25. The Group also increased EBITDA by 72.1%, returned to NPAT profitability and generated $6.6 million of operating cash flow.

A more diversified revenue mix was a key feature of the year. MEG contributed $9.7 million of revenue, Somfit and Nexus 360 SaaS revenue increased 70% to $10.2 million. The Company entered FY27 with Group open sales orders of approximately $28.3 million at 21 August 2026, of which $13.1 million was MEG open sales orders, providing a strong base for revenue conversion.

1. 72% EBITDA growth and return to profitability

Compumedics reported FY26 EBITDA of $5.4 million, up 72.1% from $3.1 million in FY25, with EBITDA margin increasing to approximately 9% of FY26 revenues from 6% of FY25 revenues. The improvement reflected operating leverage from higher revenue, tangible cost savings and higher other income. The Group returned to NPAT profitability at $0.2 million compared with a $1.3 million loss in FY25. Gross margin was 51% compared with 55% in FY25, reflecting product mix, tariffs and input cost pressures, while higher R&D expense also reflected a greater proportion of development expenditure being recognised in the period in EBITDA, rather than capitalised to Intangible Assets.

2. Connected sleep platforms continue to scale

Compumedics' connected sleep platforms continued to scale during FY26, with Somfit and Nexus 360 SaaS revenue increasing 70% to $10.2 million, driven by continued adoption across the United States and Asia. The growth was achieved ahead of the commercial release of Somfit D in the United States, where manufacturing commitments are in place and commercial readiness continues to progress.

3. MEG momentum extends into FY27

FY26 represented an important commercial milestone for Compumedics' MEG business, with MEG contributing $9.7 million of revenue compared with nil in FY25. Compumedics entered FY27 with approximately $13.1 million of MEG open orders and remains focused on progressing projects through manufacture, shipment, installation and revenue recognition.

4. Strong cash conversion and improved financial position

Net cash inflow from operating activities increased to $6.6 million from $0.4 million in FY25. Compumedics ended the year with cash and cash equivalents, less the invoice facility and overdraft, of $5.6 million, compared with $(1.0) million at 30 June 2025, an improvement of approximately $6.7 million and a stronger financial platform entering FY27.

5. Cost savings delivered and operating discipline maintained

The previously announced $2 million cost savings program was delivered during FY26 through disciplined expenditure management, organisational efficiencies and the reset of the U.S. commercial structure. Sales and marketing expenditure reduced by $3.4 million to $14.7 million. Management is carrying the same discipline into FY27 through pricing actions, supply-chain efficiencies, product cost reductions and broader overhead discipline.

OUTLOOK

Compumedics enters FY27 from a stronger financial and commercial position, with record FY26 revenue, materially higher EBITDA, improved cash generation, growing connected SaaS platforms and a substantial pipeline and order book.

The Company continues to target further double-digit revenue growth in FY27, supported by order book conversion, ongoing MEG activity, continued growth in recurring revenues and progression of Somfit D toward commercial release in the United States. Compumedics is targeting EBITDA growth at a faster rate than revenue, supported by continued operating and margin discipline.

EXECUTIVE CHAIRMAN AND CEO COMMENTARY

Compumedics Executive Chairman and CEO Dr David Burton said:

> *"FY26 represents a watershed year and a material step forward for Compumedics. We have delivered record revenue of $60.3 million, increased EBITDA by 72%, returned the Company to profitability and generated $6.6 million of operating cash flow. We also delivered the $2 million cost savings program outlined last year, reflecting the discipline introduced across the Group and the reset of our U.S. commercial operations."*
>
> *"Somfit and Nexus 360 SaaS revenue grew 70%, MEG contributed $9.7 million of revenue and Group open orders were approximately $28 million at 21 August. Our focus is now on converting this position into revenue and cash, progressing Somfit D and improving margins as we target further double-digit revenue growth and EBITDA growth at a faster rate than revenue in FY27."*
>
> **Dr David Burton** - Executive Chairman and Chief Executive Officer

The Board and management remain confident in Compumedics' growth outlook, supported by its differentiated technology platforms, expanding recurring revenue base, a solid MEG order book and global customer relationships that have been established over decades.

ABOUT COMPUMEDICS LIMITED

Compumedics Limited [ASX: CMP] is a leading global medical device company that develops, manufactures, and commercialises diagnostic technology for sleep, brain, and ultrasonic blood flow monitoring applications. The Company owns Neuroscan, based in the USA, and DWL Elektronische Systeme GmbH, based in Germany. In conjunction with these two subsidiaries, Compumedics has a broad international reach, including the Americas, Australia and Asia Pacific, Europe, and the Middle East.

Executive Chairman Dr. David Burton founded Compumedics in 1987. The same year, the Company successfully designed and installed the first fully computerised Australian sleep clinic at Epworth Hospital in Melbourne. Following this early success, Compumedics focused on developing products for the growing international sleep clinic and home monitoring markets.

Compumedics listed on the Australian Securities Exchange in 2000. Over the years, Compumedics has received numerous awards, including Australia's Exporter of the Year, and has been recognised as a Top 100 Innovator by both German and Australian Governments.

FOR FURTHER INFORMATION, PLEASE CONTACT

Dr. David Burton
Executive Chairman, CEO
P: +61 3 8420 7300
F: +61 3 8420 7399

David Lawson
Director, CFO
P: +61 3 8420 7300
F: +61 3 8420 7399

Authorised for lodgement by the Board of Directors of Compumedics Limited.